Form 4: Krystal Biotech R&D President's Latest Insider Transactions

Suma Krishnan, President of R&D at Krystal Biotech, reported significant vesting of equity awards and new grants, alongside tax-related share dispositions.

Summary

• Suma Krishnan, President of R&D at Krystal Biotech, reported multiple equity transactions on February 27, 2026.
• 22,500 Performance Stock Units (PSUs) and 4,000 Restricted Stock Units (RSUs) directly vested to Suma Krishnan.
• An additional 8,750 RSUs, 26,250 PSUs, and 5,725 RSUs indirectly vested to Suma Krishnan through her spouse, Krish S. Krishnan.
• A total of 10,236 shares (direct) and 18,528 shares (indirect via spouse) were surrendered for tax withholding at a price of $275.64 per share.
• Suma Krishnan received new grants of 18,100 stock options, 7,256 Restricted Stock Units (RSUs), and 43,536 Performance Stock Units (PSUs).
• Following these transactions, Suma Krishnan directly beneficially owns 1,428,155 shares and indirectly owns 1,500,253 shares through her spouse, 90,000 shares through SMK Trust, and 50,000 shares through Krishnan Family Trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing. The vesting of performance-based units indicates successful achievement of prior performance criteria, and the new equity grants demonstrate continued commitment to executive incentives, which can be seen as a positive signal of management's alignment with shareholder interests.

Positives

• Suma Krishnan's 22,500 Performance Stock Units (PSUs) vested, indicating the achievement of performance criteria for the year ended December 31, 2024.
• Suma Krishnan's 4,000 Restricted Stock Units (RSUs) vested as part of a four-year vesting schedule.
• Suma Krishnan's spouse, Krish S. Krishnan, had 8,750 RSUs and 5,725 RSUs vest.
• Suma Krishnan's spouse, Krish S. Krishnan, had 26,250 PSUs vest, indicating the achievement of performance criteria for the year ended December 31, 2024.
• Suma Krishnan received new grants of 18,100 stock options with an exercise price of $275.64, 7,256 Restricted Stock Units (RSUs), and 43,536 Performance Stock Units (PSUs).

Negatives

• Suma Krishnan surrendered 10,236 shares of common stock for tax withholding upon the vesting of 22,500 PSUs.
• Suma Krishnan surrendered 1,820 shares of common stock for tax withholding upon the vesting of 4,000 RSUs.
• Suma Krishnan's spouse surrendered 3,981 shares of common stock for tax withholding upon the vesting of 8,750 RSUs.
• Suma Krishnan's spouse surrendered 11,942 shares of common stock for tax withholding upon the vesting of 26,250 PSUs.
• Suma Krishnan's spouse surrendered 2,605 shares of common stock for tax withholding upon the vesting of 5,725 RSUs.

Future Outlook

The filing indicates future vesting schedules for newly granted stock options and Restricted Stock Units (RSUs) extending to February 27, 2027, and Performance Stock Units (PSUs) with a cliff vesting date of February 27, 2029, contingent on the achievement of performance criteria.

Industry Context

StockSavvy.ai notes this filing details routine insider equity compensation transactions, which are specific to the reporting person and not indicative of broader industry trends or Krystal Biotech's competitive position within the biotechnology sector.

Related Party Transactions

• Transactions involving Suma Krishnan's spouse, Krish S. Krishnan, including vesting of RSUs and PSUs and associated tax withholdings.
• Beneficial ownership through SMK Trust and Krishnan Family Trust, where Suma Krishnan and her spouse are joint beneficial owners.

Stakeholder Impact

• Shareholders: The vesting of performance-based awards suggests management achieved certain company goals, potentially aligning executive incentives with shareholder value. New equity grants reinforce long-term commitment. The use of a 10b5-1 plan indicates pre-planned transactions, reducing concerns about opportunistic selling.
• Employees: The compensation structure, including PSUs and RSUs, reflects a common approach to incentivizing key personnel based on performance and continued service.

Next Steps

• Continued service to the company by Suma Krishnan for future vesting of RSUs and PSUs.
• Achievement of performance criteria for the newly granted PSUs over a three-year period.
• Vesting of new stock options and RSUs in four equal annual installments starting February 27, 2027.
• Cliff vesting of new PSUs on February 27, 2029, if performance criteria are met.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, including the vesting of equity awards, associated tax withholdings, and new grants. While the vesting of performance-based units is a positive indicator of past performance achievement, and new grants show continued alignment, these are standard events for a public company executive. There are no extraordinary sales or purchases that would suggest a significant shift in insider sentiment or warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new fundamental information to alter an existing investment thesis.

Keywords

Krystal Biotech, KRYS, Suma Krishnan, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Performance Stock Units, Equity Compensation, Executive Compensation, Beneficial Ownership